Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PLRZ Polyrizon Ltd.

盘前交易 02-26 08:35:27 EST

13.54

-0.46

-3.29%

盘前13.50

-0.04-0.30%

08:33 EST

最高14.00	最低13.50	成交量2.31万
今开14.00	昨收14.00	日振幅3.57%
总市值1,410万	流通市值1,350万	总股本104.17万
成交额31.94万	换手率2.32%	流通股本99.68万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":13.54,"timestamp":1772053200000,"preClose":14,"halted":0,"volume":23113,"hourTrading":{"tag":"盘前","latestPrice":13.5,"preClose":13.54,"latestTime":"08:33 EST","volume":1480,"amount":20725.58404,"timestamp":1772112818211,"change":-0.04,"changeRate":-0.002954,"amplitude":0.062777},"delay":0,"changeRate":-0.03285714285714292,"floatShares":996800,"shares":1041700,"eps":-0.71144193,"marketStatus":"盘前交易","change":-0.46,"latestTime":"02-26 08:35:27 EST","open":14,"high":14,"low":13.5,"amount":319352.205435,"amplitude":0.035714,"askPrice":15.46,"askSize":100,"bidPrice":13.4,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-0.71144193,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772116200000},"marketStatusCode":1,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":13.54,"preHourTrading":{"tag":"盘前","latestPrice":13.5,"preClose":13.54,"latestTime":"08:33 EST","volume":1480,"amount":20725.58404,"timestamp":1772112818211,"change":-0.04,"changeRate":-0.002954,"amplitude":0.062777},"postHourTrading":{"tag":"盘后","latestPrice":13.5,"preClose":13.54,"latestTime":"17:18 EST","volume":5022,"amount":67870.9,"timestamp":1772057899324,"change":-0.04,"changeRate":-0.002954,"amplitude":0.032496},"volumeRatio":0.6309028548092135},"requestUrl":"/m/hq/s/PLRZ","defaultTab":"news","newsList":[{"id":"1121429365","title":"Polyrizon宣布其纳洛酮制剂研究取得积极成果，鼻腔沉积特性优于市售参照产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1121429365","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121429365?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:14","pubTimestamp":1772111644,"startTime":"0","endTime":"0","summary":"生物制药公司Polyrizon Ltd.近日公布了一项关于其自主研发的纳洛酮鼻喷雾制剂的实验研究结果。研究数据显示，该公司的创新配方在关键的鼻腔沉积性能方面表现出显著优势，其沉积效果明显优于目前市面上的主流参照产品。\n这一积极成果标志着Polyrizon在药物递送技术领域取得了重要进展，为其纳洛酮产品的后续开发奠定了坚实基础。纳洛酮作为一种用于逆转阿片类药物过量的重要抢救药物，其鼻腔给药形式的有效性至关重要。此次研究的成功，预示着该配方有望为紧急用药场景提供更高效、更可靠的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2611018503","title":"Polyrizon Ltd.盘中异动 临近午盘股价大涨5.06%报13.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611018503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611018503?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:41","pubTimestamp":1770914502,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日00时41分，Polyrizon Ltd.股票出现异动，股价急速拉升5.06%。截至发稿，该股报13.50美元/股，成交量2.2526万股，换手率2.16%，振幅5.60%。Polyrizon Ltd.股票所在的生物技术行业中，整体跌幅为0.14%。Polyrizon Ltd.公司简介：Polyrizon Ltd是一家处于临床开发阶段的生物技术公司，专门开发鼻用凝胶，以提供抵御各种病毒的预防性治疗，包括某些 COVID-19 变种，这些变种也被认为比病毒的原始毒株引起更多的感染并传播得更快，流感、过敏原和其他毒素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213004142a49d39af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213004142a49d39af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"gpt_icon":0},{"id":"1178859253","title":"Polyrizon Ltd.：签署谅解备忘录后30天内有望达成最终协议，尚待尽职调查","url":"https://stock-news.laohu8.com/highlight/detail?id=1178859253","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178859253?lang=zh_cn&edition=full","pubTime":"2026-02-10 19:59","pubTimestamp":1770724751,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 宣布，在签署谅解备忘录后，预计将在30天内完成最终协议的签订。此项进程的推进，将以顺利完成尽职调查为前提条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2610610896","title":"Polyrizon Ltd.盘中异动 早盘股价大跌6.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610610896","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610610896?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:52","pubTimestamp":1770648721,"startTime":"0","endTime":"0","summary":"北京时间2026年02月09日22时52分，Polyrizon Ltd.股票出现波动，股价大幅跳水6.34%。截至发稿，该股报12.03美元/股，成交量4461股，换手率0.43%，振幅5.50%。Polyrizon Ltd.股票所在的生物技术行业中，整体跌幅为0.07%。Polyrizon Ltd.公司简介：Polyrizon Ltd是一家处于临床开发阶段的生物技术公司，专门开发鼻用凝胶，以提供抵御各种病毒的预防性治疗，包括某些 COVID-19 变种，这些变种也被认为比病毒的原始毒株引起更多的感染并传播得更快，流感、过敏原和其他毒素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020922520197a58300&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020922520197a58300&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"gpt_icon":0},{"id":"1183826025","title":"Polyrizon与合作伙伴达成协议，共同开发专有非致幻性神经可塑性药物鼻腔制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1183826025","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183826025?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:56","pubTimestamp":1770382574,"startTime":"0","endTime":"0","summary":"生物医药公司Polyrizon Ltd.近日宣布，已签署一项重要合作协议，旨在推进其专有的非致幻性神经可塑性药物（Neuroplastogen）鼻腔制剂的研发进程。该合作标志着公司在创新神经科学疗法领域迈出了关键一步。\n此次开发的鼻腔制剂采用了独特的技术路径，旨在通过鼻内给药方式靶向神经系统，促进神经可塑性，同时避免了传统精神活性物质常见的致幻副作用。这一特性使其在治疗抑郁症、创伤后应激障碍等神经系统相关疾病方面具有广阔的临床应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","CMND","BK4007"],"gpt_icon":0},{"id":"1173106061","title":"Clearmind Medicine签署开发协议，推进其专有无致幻神经塑性药物Meai的鼻内制剂研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1173106061","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173106061?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:56","pubTimestamp":1770382573,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. 近日与Polyrizon Ltd. 达成一项开发合作协议，旨在加速其专有无致幻神经塑性化合物Meai的鼻内制剂研发进程。该合作将结合Clearmind在神经科学领域的专长与Polyrizon在药物递送技术方面的优势，共同推进新型治疗方案的开发。此次合作标志着公司在非致幻性神经可塑性药物研发领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4007","CMND"],"gpt_icon":0},{"id":"2608582476","title":"Polyrizon Ltd.股价飙升12.25% 市值涨164.86万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608582476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608582476?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:35","pubTimestamp":1770042902,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时35分，Polyrizon Ltd.股票出现波动，股价急速上涨12.25%。截至发稿，该股报12.92美元/股，成交量1.5876万股，换手率1.52%，振幅4.17%。Polyrizon Ltd.股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Polyrizon Ltd.、Verrica制药涨幅较大，60 Degrees Pharmaceuticals, Inc.、Vivosim Labs, Inc.、Vyome Holdings, Inc.较为活跃，换手率分别为248.27%、17.03%、14.96%，振幅较大的相关个股有Bioatla, Inc.、Context Therapeutics Inc.、天演药业，振幅分别为27.73%、18.39%、15.27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202223502a6cab6b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202223502a6cab6b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"gpt_icon":0},{"id":"1117300089","title":"Polyrizon启动Nasarix™过敏阻断剂可用性研究项目，推进监管审批进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1117300089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117300089?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:27","pubTimestamp":1769092073,"startTime":"0","endTime":"0","summary":"Polyrizon有限公司在推进其主打产品Nasarix™过敏阻断剂的监管审批道路上迈出了关键一步，正式启动了该产品的可用性研究项目。这一举措旨在评估产品的实际使用体验与性能，为后续向监管机构提交申请收集必要的数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1108909694","title":"Polyrizon Ltd. 董事会批准进行选择性投资，预计将产生近期收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1108909694","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108909694?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:46","pubTimestamp":1768311997,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 宣布，其董事会已正式批准一项战略计划，将着手进行一系列选择性投资。公司方面表示，这些经过精心筛选的投资项目，预计将在短期内为公司带来可观的收入增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1176001861","title":"Polyrizon Ltd. 初期战略聚焦高潜力领域运营公司，涵盖国防、航空及人工智能","url":"https://stock-news.laohu8.com/highlight/detail?id=1176001861","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176001861?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:44","pubTimestamp":1768311852,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 正将其初步发展重心，精准锁定于多个高增长潜力行业的运营公司。其战略布局尤其关注国防、航空以及人工智能等前沿领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1109995262","title":"Polyrizon 向 FDA 提交 PL-16 病毒阻断剂的前期指定请求，旨在减少对流感和感冒病毒的暴露","url":"https://stock-news.laohu8.com/highlight/detail?id=1109995262","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109995262?lang=zh_cn&edition=full","pubTime":"2025-12-19 21:20","pubTimestamp":1766150456,"startTime":"0","endTime":"0","summary":"Polyrizon 向 FDA 提交 PL-16 病毒阻断剂的前期指定请求，旨在减少对流感和感冒病毒的暴露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1122590563","title":"Polyrizon宣布良好的渗透动力学，支持其鼻用纳洛酮水凝胶项目的推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1122590563","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122590563?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:15","pubTimestamp":1765458914,"startTime":"0","endTime":"0","summary":"Polyrizon宣布良好的渗透动力学，支持其鼻用纳洛酮水凝胶项目的推进","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1118176425","title":"Polyrizon发布与市场上市的鼻用纳洛酮产品相比的积极粘附性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1118176425","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118176425?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:29","pubTimestamp":1764772150,"startTime":"0","endTime":"0","summary":"Polyrizon发布与市场上市的鼻用纳洛酮产品相比的积极粘附性结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1108302800","title":"Polyrizon宣布按1至6的比例进行普通股反向拆分 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1108302800","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108302800?lang=zh_cn&edition=full","pubTime":"2025-11-25 21:05","pubTimestamp":1764075912,"startTime":"0","endTime":"0","summary":"Polyrizon宣布按1至6的比例进行普通股反向拆分 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2583063750","title":"Polyrizon Ltd.盘中异动 股价大跌6.41%报0.721美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583063750","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583063750?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:30","pubTimestamp":1763130625,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日22时30分，Polyrizon Ltd.股票出现异动，股价快速下挫6.41%。截至发稿，该股报0.721美元/股，成交量2.8445万股，换手率0.47%，振幅2.47%。Polyrizon Ltd.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Cidara Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.、Invivyd, Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Clearmind Medicine Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为686.43%、33.92%、25.30%，振幅较大的相关个股有Silo Pharma, Inc.、Precigen, Inc.、Fennec Pharmaceuticals Inc.，振幅分别为9.19%、7.25%、7.15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142230259504b00d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142230259504b00d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"gpt_icon":0},{"id":"1106685558","title":"Polyrizon Ltd.公布积极的临床前研究结果：Pl-14显示出令人鼓舞的过敏原阻断效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1106685558","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106685558?lang=zh_cn&edition=full","pubTime":"2025-10-06 20:22","pubTimestamp":1759753369,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd.宣布其候选药物Pl-14在临床前研究中取得积极进展，该药物在过敏原阻断方面展现出令人鼓舞的疗效表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.polyrizon-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0294},{"period":"1month","weight":-0.1191},{"period":"3month","weight":3.3231},{"period":"6month","weight":1.0703},{"period":"1year","weight":-0.9896},{"period":"ytd","weight":0.5948}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Polyrizon Ltd.于2005年1月在以色列注册成立。该公司是一家处于发展阶段的生物技术公司，专门开发以鼻喷雾剂形式交付的创新医疗器械水凝胶，该水凝胶在鼻腔内形成一层薄薄的基于水凝胶的防护屏障，可以防止病毒和过敏原接触鼻上皮组织。该公司的C&C水凝胶技术由天然存在的构建块的混合物组成，以鼻喷雾剂的形式提供，并可用作“生物面具”，在鼻腔内有一层薄薄的防护屏障。该公司正在进一步开发其专有的C&C水凝胶技术的某些方面，例如生物粘附性和在鼻腔沉积部位的延长保留时间，以用于鼻内给药。该公司将其专注于API鼻腔给药的独立平台技术称为T&T。","exchange":"NASDAQ","name":"Polyrizon Ltd.","nameEN":"Polyrizon Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Polyrizon Ltd.(PLRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Polyrizon Ltd.,PLRZ,Polyrizon Ltd.股票,Polyrizon Ltd.股票老虎,Polyrizon Ltd.股票老虎国际,Polyrizon Ltd.行情,Polyrizon Ltd.股票行情,Polyrizon Ltd.股价,Polyrizon Ltd.股市,Polyrizon Ltd.股票价格,Polyrizon Ltd.股票交易,Polyrizon Ltd.股票购买,Polyrizon Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Polyrizon Ltd.(PLRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}